证券代码：600329 证券简称：达仁堂 编号：临 2023-022 号 津药达仁堂集团股份有限公司 关于召开业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、说明会类型 津药达仁堂集团股份有限公司（以下简称"公司"）已分别于 2023 年 4 月 1 日、2023 年 4 月 29 日发布了 2022 年年度报告与 2023 年第一季度报告（详见上海证券交易所网站 www.sse.com.cn）。为便 于广大投资者更深入全面地了解公司经营业绩等情况，公司定于2023 年 5 月 30 日（星期二）下午 15:00—16:00 举行"业绩说明会"（以下 简称"说明会"）。 二、说明会召开时间、地点 召开时间：2023 年 5 月 30 日（星期二）下午 15:00—16:00 召开地点：东方财富路演 1 会议召开时间：2023 年 5 月 30 日（星期二）下午 15:00—16:00 会议召开地点：东方财富路演 （https://roadshow.eastmoney.com/luyan/4 ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 2,154,405,776.85, representing a year-on-year increase of 14.03%[4] - Net profit attributable to shareholders was RMB 400,788,396.53, showing a significant increase of 100.79% compared to the same period last year[4] - Basic and diluted earnings per share both stood at RMB 0.52, marking a 100% increase year-on-year[4] - Total operating revenue for Q1 2023 reached ¥2,154,405,776.85, an increase of 14.05% compared to ¥1,889,294,355.26 in Q1 2022[16] - Net profit for Q1 2023 was ¥397,782,701.63, compared to ¥202,246,413.81 in Q1 2022, representing a growth of 96.59%[18] - Earnings per share for Q1 2023 were ¥0.52, doubling from ¥0.26 in Q1 2022[19] - The total comprehensive income for Q1 2023 was ¥397,884,789.40, compared to ¥201,906,275.33 in Q1 2022, reflecting an increase of 97.00%[18] Cash Flow - The net cash flow from operating activities reached RMB 186,966,594.00, reflecting a year-on-year growth of 137.21%[4] - Cash inflow from operating activities for Q1 2023 was approximately ¥2.21 billion, an increase of 24% compared to ¥1.78 billion in Q1 2022[20] - Net cash flow from operating activities reached ¥186.97 million in Q1 2023, up from ¥78.82 million in Q1 2022, representing a growth of 137%[20] - Total cash inflow from investment activities was ¥116.36 million in Q1 2023, a decrease of 73% from ¥435.31 million in Q1 2022[21] - Net cash flow from financing activities was ¥323.50 million in Q1 2023, compared to a net outflow of ¥17.52 million in Q1 2022[21] - The net increase in cash and cash equivalents for Q1 2023 was approximately ¥582.34 million, compared to an increase of ¥411.10 million in Q1 2022[21] Assets and Liabilities - Total assets at the end of the reporting period were RMB 10,866,527,859.66, up 6.99% from the end of the previous year[5] - The total liabilities have increased to RMB 3,560,725,598.61 from RMB 3,333,434,867.96, suggesting a rise in financial obligations[14] - The company's total liabilities increased to ¥3,933,820,819.32 in Q1 2023 from ¥3,605,028,900.58 in Q1 2022, marking a rise of 9.09%[17] - The total equity attributable to shareholders reached ¥6,905,220,131.40 in Q1 2023, up from ¥6,521,460,534.99 in Q1 2022, an increase of 5.88%[17] Expenses - Sales expenses rose by 39% primarily due to the increase in sales revenue[9] - Financial expenses increased by 64%, mainly attributed to higher interest costs[9] - Research and development expenses for Q1 2023 were ¥24,195,352.76, compared to ¥19,332,928.57 in Q1 2022, indicating a rise of 25.31%[17] - Cash paid to employees in Q1 2023 was ¥243.44 million, an increase of 22% from ¥199.52 million in Q1 2022[20] - Cash paid for taxes in Q1 2023 was ¥229.69 million, significantly higher than ¥98.40 million in Q1 2022, indicating a growth of 133%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,433, with the largest shareholder, Tianjin Pharmaceutical Group Co., Ltd., holding 331,120,528 shares, accounting for 42.811% of the total[10] Other Income - The company reported a 655% increase in other income, mainly from government subsidies received[9] - The company reported a financial income of ¥12,287,594.48 in Q1 2023, down from ¥13,078,314.45 in Q1 2022[17] Current Assets - As of March 31, 2023, the company's total current assets amount to RMB 7,903,764,059.62, an increase from RMB 7,245,444,756.23 in the previous year[13] - The company's cash and cash equivalents stand at RMB 3,455,307,279.55, compared to RMB 2,882,523,954.61 as of December 31, 2022, reflecting a significant increase[13] - Accounts receivable have risen to RMB 2,440,287,659.57 from RMB 2,146,213,416.31 year-over-year, indicating a growth in sales or credit terms[13] Financial Management - The company reported a decrease in accounts payable, which fell to RMB 686,731,735.62 from RMB 724,326,434.25, indicating improved cash flow management[14] - The company has a significant increase in short-term borrowings, which rose to RMB 351,276,795.73 from RMB 101,638,515.28[14] Intangible Assets - The company has maintained a stable level of intangible assets, which increased to RMB 332,127,671.68 from RMB 281,127,790.71[14] Product Development - The company has not disclosed any significant new product developments or market expansion strategies in the current report[12]

Financial Performance - The company achieved a net profit of ¥861,793,906.84 in 2022, representing a 12.05% increase compared to ¥769,144,377.12 in 2021[21]. - Total operating revenue for 2022 was ¥8,249,249,565.18, marking a 19.42% increase from ¥6,907,544,256.00 in 2021[21]. - The basic earnings per share rose to ¥1.12 in 2022, a 12.00% increase from ¥1.00 in 2021[23]. - The weighted average return on equity improved to 13.15% in 2022, up from 12.64% in 2021[23]. - The company reported a net profit of ¥769,227,070.99 after deducting non-recurring gains and losses, a 3.94% increase from ¥740,056,524.95 in 2021[21]. - The net profit attributable to shareholders for the fourth quarter was CNY 132,833,170.58, with a total annual net profit of CNY 1,061,793,007.84, reflecting a decrease compared to the previous year[26]. - The company achieved a total revenue of CNY 8,249,249,565.18 in 2022, representing a year-on-year increase of 19.42% compared to CNY 6,907,544,256.00 in the previous year[66]. - The net profit attributable to the parent company for 2022 was CNY 86,179,390.00, with total assets amounting to CNY 1,015,698,200.00 and net assets of CNY 655,195,310.00[64]. Cash Flow and Investments - Cash flow from operating activities decreased by 20.55% to ¥677,245,078.23 in 2022, down from ¥852,401,231.63 in 2021[21]. - The net cash flow from operating activities in the fourth quarter was CNY 550,771,466.60, significantly higher than the previous quarters[26]. - The company reported a net cash flow from investing activities of -12.28 million RMB, a significant improvement of 96.06% compared to the previous period[84]. - The company increased its long-term equity investments to CNY 760.19 million by the end of 2022, up from CNY 729.66 million at the beginning of the year[121]. - The company invested CNY 45 million in acquiring Tianjin Darentang Jingzhong Traditional Chinese Medicine, achieving 100% ownership[122]. Research and Development - In 2022, the company invested CNY 151 million in R&D, enhancing the quality standards of major products and improving drug safety and treatment experience[42]. - The company’s R&D investment accounted for 1.83% of its operating revenue, with a capitalized proportion of 4.17%[114]. - The R&D investment for the Qingfei Xiaoyan Wan major product's secondary development was CNY 107.15 million, reflecting a year-on-year increase of 108.4%[115]. - The company is actively developing two generic drugs for consistency evaluation, aiming to improve market competitiveness[107]. - The company has a total of 402 patents, including 256 invention patents, supporting its innovation and product development capabilities[62]. Market Strategy and Expansion - The company implemented a "1+5" strategic layout focusing on brand leadership and five related industries, including traditional Chinese medicine and health products[34]. - The company aims to enhance the competitiveness of the "Darentang" brand and has initiated trademark registrations and subsidiary name changes to support this strategy[34]. - The company plans to explore a combined medical and health model that incorporates traditional Chinese medicine, enhancing its service offerings[34]. - The company is focusing on the integration of traditional Chinese medicine resources and the establishment of a national chain of "Darentang" pharmacies[34]. - The company plans to expand its market presence and invest in new product development to sustain growth in the coming years[71]. Operational Efficiency - The company has established a marketing network covering the medical market, retail market, third terminal, and online channels, achieving steady progress in operational targets[44]. - The company has integrated its sales platforms, including the establishment of the commercial sales division in 2022 to operate generic drug products[38]. - The company streamlined its management structure, reducing the number of departments from 14 to 12 to better meet strategic development needs[40]. - The company is focused on optimizing smart manufacturing processes to reduce costs and improve quality, implementing lean management principles and enhancing production efficiency[140]. - The company has established a centralized procurement management system for medicinal materials, focusing on cost reduction, quality assurance, and supply stability[48]. Corporate Governance and Management - The company operates under a robust governance structure, having listings in both Singapore and Shanghai, which enhances its capital operation and financing capabilities[63]. - The company has a board of directors consisting of 8 members, with 4 independent directors[158]. - The company’s board of directors is responsible for determining the remuneration of directors and supervisors, authorized by the shareholders' meeting[167]. - The company has established specialized committees within the board, including an audit committee and a strategic committee[175]. - The company has a clear cash dividend policy that aligns with regulatory requirements and shareholder interests[184]. Social Responsibility and Compliance - The company is committed to social responsibility and compliance, focusing on employee welfare, environmental protection, and ESG initiatives as part of its operational strategy[144]. - The company invested CNY 10.81 million in environmental protection during the reporting period[196]. - The company has strengthened its internal control system, adding 6 new regulations in 2022[192]. - The company is required to ensure compliance with new regulations regarding traditional Chinese medicine by July 2023, which mandates the submission of safety information for re-registration[148]. - The company is committed to fostering a high-performance culture by optimizing its human resource management system and implementing performance evaluation mechanisms[40]. Risks and Challenges - The company faces risks related to policy changes in the pharmaceutical industry, including the impact of centralized procurement and pricing reforms, which may introduce market uncertainties[145]. - The company is also exposed to cost pressures from rising raw material prices and labor costs, which could affect profitability and operational stability[145]. - The medical and OTC market profitability may decline due to increased buyer power represented by medical insurance payments and intensified competition within the industry[146]. - The company faces potential risks in new drug development, including failures, delays in market entry, and slow growth post-launch due to strict regulatory approvals and market conditions[147]. - The regulatory environment for drug quality has intensified since the implementation of the Drug Administration Law in December 2019, increasing the responsibility of drug marketing authorization holders[148].

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,788,247,682.39, representing a year-on-year increase of 4.47%[4] - The net profit attributable to shareholders for the same period was ¥260,175,685.17, reflecting a significant increase of 30.77% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥184,375,376.29, which showed a decrease of 3.73% year-on-year[4] - The basic earnings per share for Q3 2022 was ¥0.34, up by 30.77% from the same period last year[5] - The total profit for Q3 2022 was approximately ¥847.92 million, an increase from ¥763.91 million in Q3 2021, representing a growth of about 11.1%[21] - The net profit for Q3 2022 reached approximately ¥746.21 million, compared to ¥677.00 million in Q3 2021, indicating a year-over-year increase of around 10.2%[21] - The net profit attributable to shareholders of the parent company was approximately ¥728.96 million, up from ¥661.51 million in the same quarter last year, reflecting a growth of about 10.1%[22] - The basic earnings per share for Q3 2022 was ¥0.95, compared to ¥0.86 in Q3 2021, marking an increase of approximately 10.5%[22] Assets and Liabilities - The total assets at the end of the reporting period reached ¥9,749,983,806.96, an increase of 7.53% compared to the end of the previous year[5] - The total current assets amounted to 6,915,032,966.25 yuan, an increase from 6,424,993,578.77 yuan at the end of 2021[16] - Non-current assets totaled ¥2,834,950,840.71, an increase from ¥2,642,091,427.30 in the previous year[18] - Current liabilities increased to ¥2,680,520,189.59 from ¥2,433,902,114.44, indicating a rise of 10.14%[18] - The company holds 698,495,037.33 yuan in long-term equity investments as of September 30, 2022[16] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥126,473,611.63, which decreased by 81.32% compared to the previous year[5] - The net cash flow from operating activities for Q3 2022 was approximately ¥126.47 million, a significant decrease from ¥677.11 million in Q3 2021[25] - Cash inflow from investment activities in Q3 2022 totaled approximately ¥653.66 million, compared to ¥189.56 million in Q3 2021, showing a substantial increase[25] - The net cash flow from investment activities for Q3 2022 was approximately ¥155.48 million, a recovery from a net outflow of ¥273.60 million in Q3 2021[25] - The company reported a total operating cash outflow of approximately ¥5.36 billion in Q3 2022, compared to ¥4.84 billion in Q3 2021, reflecting an increase of about 10.5%[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,884[12] - Tianjin Pharmaceutical Group Co., Ltd. is the largest shareholder, holding 331,120,528 shares, accounting for 42.811% of the total shares[12] - The number of shares held by the top ten shareholders includes significant foreign and domestic entities, indicating a diverse shareholder base[12] - The company has not disclosed any related party relationships among the top ten shareholders[13] Strategic Initiatives - The company has seen a 132.07% increase in capitalized research and development expenses, indicating a focus on innovation and new product development[10] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[10] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the provided content[20] Revenue and Costs - Total revenue for the first three quarters of 2022 reached ¥5,563,011,492.12, an increase of 3.94% compared to ¥5,352,222,520.14 in the same period of 2021[19] - Total operating costs for the third quarter amounted to ¥4,908,870,636.98, up from ¥4,743,067,407.38 year-over-year[20] - Operating profit for the third quarter was ¥850,221,307.98, compared to ¥756,079,156.11 in the previous year, reflecting a growth of 12.43%[20] - Research and development expenses for the first three quarters were ¥92,259,923.53, slightly down from ¥94,465,763.49 in the previous year[20] Accounts Receivable and Inventory - The company reported a significant increase in accounts receivable by 54.69%, primarily due to an increase in receivables from sales[10] - Accounts receivable increased to 2,377,623,755.60 yuan from 1,536,992,972.81 yuan year-over-year[16] - Inventory decreased to 1,343,866,721.60 yuan from 1,525,088,939.42 yuan year-over-year[16]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 3,774,763,809.73, representing a 3.69% increase compared to CNY 3,640,421,324.94 in the same period last year[16]. - The net profit attributable to shareholders for the first half of 2022 was CNY 468,785,051.09, a slight increase of 1.35% from CNY 462,548,368.85 in the previous year[16]. - The basic earnings per share for the first half of 2022 was CNY 0.61, reflecting a 1.67% increase from CNY 0.60 in the same period last year[17]. - The diluted earnings per share also stood at CNY 0.61, which is a 1.67% increase compared to CNY 0.60 in the previous year[18]. - The company reported a 4.33% increase in net profit attributable to shareholders after deducting non-recurring gains and losses, amounting to CNY 464,246,739.81 compared to CNY 444,974,234.80 last year[16]. - The company reported a total profit for the first half of 2022 of CNY 549.82 million, compared to CNY 539.57 million in the same period of 2021, reflecting a growth of 1.5%[125]. - The total comprehensive income for the first half of 2022 was CNY 476.93 million, slightly up from CNY 471.37 million year-on-year[126]. Cash Flow and Financial Position - The net cash flow from operating activities decreased significantly by 75.92%, amounting to CNY 89,054,915.47 compared to CNY 369,883,945.76 in the same period last year[16]. - The company reported a significant increase of 124.56% in accounts receivable, reaching approximately CNY 2.17 billion, compared to CNY 1.54 billion last year[59]. - Cash and cash equivalents rose to CNY 2,596,936,387.08 from CNY 2,283,181,481.69, marking an increase of approximately 13.75%[117]. - The company reported a cash outflow from financing activities of CNY 385,237,457.71, compared to CNY 224,065,526.13 in the previous year, leading to a net cash flow from financing activities of CNY -363,706,187.30[134]. - The total assets at the end of the reporting period were CNY 9,290,068,670.30, which is a 2.46% increase from CNY 9,067,085,006.07 at the end of the previous year[16]. - Total liabilities rose to CNY 2,694,574,521.57 from CNY 2,553,255,875.58, reflecting an increase of around 5.55%[119]. Research and Development - The company possesses 402 patents, including 253 invention patents, reflecting strong research and development capabilities[40]. - The company is enhancing its research and development efforts, with key projects including the quality standard improvement of Su Xiao Jiu Xin Wan and the study of Qing Yan Di Wan's effects on coronavirus[53]. - Research and development expenses decreased by 16.66% to approximately CNY 55 million from CNY 66 million, indicating a more balanced expenditure[56]. Market and Industry Insights - The company operates in the green traditional Chinese medicine sector, covering the entire industry chain from cultivation to retail[22]. - The market share of the flagship product, "Su Xiao Jiu Xin Wan," increased from 2.43% in 2016 to 3.21% in 2021 in public health institutions[25]. - The overall revenue of China's pharmaceutical manufacturing industry in the first half of 2022 was RMB 1,400.78 billion, a decrease of 0.6% year-on-year[31]. - The industry’s total profit in the same period was RMB 220.95 billion, reflecting a decline of 27.6% compared to the previous year[31]. Strategic Initiatives - The company launched 28 new products in the first half of 2022, focusing on integrating resources and enhancing brand strength[45]. - The company is exploring the integration of online and offline channels in the healthcare sector, leveraging digital management systems for improved efficiency[36]. - The company is actively developing the Daren Tang chain pharmacy and exploring new operational models for Daren Tang hospitals[44]. Environmental and Regulatory Compliance - The company is classified as a key pollutant discharge unit in Tianjin, with three subsidiaries recognized for their environmental impact[81]. - Pollution control facilities at the company's subsidiaries are operating normally, including VOCs and wastewater treatment systems[82]. - The company has established environmental self-monitoring plans to comply with pollution discharge requirements[85]. Related Party Transactions - The controlling shareholder, Tianjin Pharmaceutical Group Co., Ltd., committed to strictly executing related party transactions according to the contract, ensuring no interference from its controlling position[88]. - The company reported a total related party transaction amount of 245,596,000.00 RMB, accounting for 10.17% of similar transactions[97]. Challenges and Risks - The company faces risks from policy changes in the pharmaceutical industry, including the implementation of the "three medical" management system and the ongoing reforms in medical insurance payment methods[69]. - Rising raw material costs in the traditional Chinese medicine sector pose a significant risk to the company's cost management and profitability[70]. - The company anticipates challenges in maintaining profit margins due to increased buyer power in the medical insurance sector and intensified competition in retail channels[70]. Corporate Governance - The company completed the renaming process, changing its name to Tianjin Daren Tang Group Co., Ltd. on May 18, 2022, marking the start of a new development phase[42]. - Zhang Yu was appointed as the Chief Manufacturing Officer (CPO) on April 28, 2022[77]. - The company does not plan to distribute profits or increase capital reserves for the half-year period[78].

Financial Performance - In 2021, the company achieved a revenue of CNY 6,907,544,256, representing a 4.60% increase compared to CNY 6,603,652,015 in 2020[19] - The net profit attributable to shareholders was CNY 769,144,377, marking a 16.24% increase from CNY 661,704,350 in the previous year[19] - The company's total assets at the end of 2021 were CNY 9,067,085,006, a 9.46% increase from CNY 8,283,387,680 in 2020[20] - The basic earnings per share for 2021 was CNY 1.00, up 16.28% from CNY 0.86 in 2020[21] - The net cash flow from operating activities was CNY 740,056,524.95, reflecting a 16.88% increase from CNY 633,187,164.91 in 2020[19] - The company's net assets attributable to shareholders increased by 9.57% to CNY 6,364,477,575.04 at the end of 2021[20] - The company reported a weighted average return on equity of 12.64%, an increase of 0.81 percentage points from 11.83% in 2020[21] Dividend Distribution - The company plans to distribute a cash dividend of CNY 5.0 per 10 shares to all shareholders, totaling CNY 231,972,922.80 for the year[4] Research and Development - The company invested CNY 147 million in scientific research projects throughout 2021, completing 113 projects[33] - The company achieved an online exposure of over 526 million times through various brand promotion activities targeting the 40+ age group[31] - The company completed research and analysis for 12 key traditional Chinese medicine products and proposed 55 research directions, forming 27 project suggestions for continuous technological innovation[33] - The company’s R&D expenses increased by 7.94% to CNY 161,052.22 million, reflecting a commitment to innovation[54] - The company has a product portfolio of 599 approved drug varieties, including 114 exclusive products and 223 varieties covered by national medical insurance[50] - The company holds 390 patents, including 252 invention patents, supporting its strong R&D capabilities[51] Market Expansion and Product Development - The company actively promoted nine key products into clinical application guidelines, enhancing their market presence[29] - The company expanded its retail presence, increasing the number of active medical sales accounts to 104[30] - The company is focused on the modernization of traditional Chinese medicine, emphasizing the development of new drugs based on ancient classic formulas and enhancing the quality of traditional Chinese medicine[119] - The company aims to enhance its market position by focusing on growth in the medical sector while seeking breakthroughs in the retail sector[80] - The company is actively developing new products and technologies to adapt to changing industry policies and enhance its competitive edge[80] Industry Trends and Challenges - The pharmaceutical industry exhibits weak cyclicality, with a strong demand for medical services that is less correlated with economic cycles[40] - The ongoing reforms in drug procurement and payment systems are expected to create uncertainties in the industry[43] - The company is focusing on enhancing its research and development capabilities in response to the competitive landscape shaped by centralized procurement[43] - The company faces risks related to policy changes, rising raw material costs, and increased competition in the healthcare market, which may impact profitability[140] Governance and Compliance - The company held 1 annual general meeting and 2 extraordinary general meetings during the reporting period, ensuring compliance with governance regulations and protecting shareholders' rights[145] - The company has established a drug quality management system to ensure compliance with the Drug Administration Law and the Drug Quality Management Standards, enhancing the quality management level[144] - The company has implemented a quality internal audit system to continuously improve its quality management system[144] - The company has committed to maintaining independence from its controlling shareholder in terms of business, personnel, assets, and finance[147] Environmental Management - The company is classified as a key pollutant discharge unit, with specific measures in place for environmental management and compliance[191] - Pollution prevention facilities at the company's plants are operational, including wastewater treatment and air pollution control systems[192][193] - The company has implemented low-emission operations in 2021, achieving a nitrogen oxide emission concentration limit of below 50 mg/m³ through boiler upgrades and low-nitrogen burner modifications[198] - The wastewater treatment process meets the "Comprehensive Wastewater Discharge Standard" (GB8978) requirements, with treated water being discharged into the municipal sewage system[198] Employee Management and Compensation - The company employed a total of 4,650 staff, with 3,694 in the parent company and 956 in major subsidiaries[174] - The workforce includes 1,528 production personnel, 1,745 sales personnel, 707 technical staff, 214 financial staff, and 456 administrative staff[174] - The company emphasizes performance-based compensation to incentivize employees and enhance overall corporate performance[175] - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to RMB 8.6633 million and SGD 110,000[161] Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% based on new product launches and market expansion strategies[158] - The company aims to reduce operational costs by 15% through efficiency improvements and automation[158] - Future guidance indicates an expected EBITDA margin of 30% for the upcoming fiscal year, reflecting strong operational performance[156]

Financial Performance - The company's operating revenue for Q3 2021 was ¥1,711,801,195.20, representing a year-over-year increase of 2.71%[4] - The net profit attributable to shareholders for Q3 2021 was ¥198,962,360.28, reflecting a significant increase of 29.75% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥191,517,969.41, up by 29.79% year-over-year[4] - The basic earnings per share for Q3 2021 was ¥0.26, an increase of 30.00% year-over-year[5] - The net profit for Q3 2021 was CNY 677,003,684.99, an increase of 37.2% compared to CNY 493,390,349.14 in Q3 2020[23] - The total profit for Q3 2021 reached CNY 763,914,695.63, up 35.4% from CNY 564,276,364.09 in the same period last year[23] - The operating profit for Q3 2021 was CNY 756,079,156.11, compared to CNY 581,136,003.29 in Q3 2020, reflecting a growth of 30.1%[23] - The total comprehensive income for Q3 2021 was CNY 667,389,411.49, up 37.0% from CNY 487,676,610.91 in Q3 2020[24] - The company achieved a net profit margin of 20%, reflecting strong operational efficiency and cost management[27] Cash Flow and Assets - The net cash flow from operating activities for Q3 2021 was ¥307,226,722.62, showing a remarkable increase of 186.23% compared to the same period last year[5] - The net cash flow from operating activities increased by 64% to approximately ¥677 million, attributed to higher cash received from sales of goods and services[13] - The cash flow from operating activities for the first nine months of 2021 was CNY 5,514,599,915.20, an increase of 26.4% from CNY 4,358,738,082.72 in the same period of 2020[25] - The cash and cash equivalents at the end of Q3 2021 amounted to CNY 2,147,959,493.98, an increase from CNY 1,285,869,412.74 at the end of Q3 2020[26] - The company reported a net cash outflow from investing activities of CNY -273,603,499.01 in Q3 2021, compared to CNY -371,289,197.88 in Q3 2020[25] - The company incurred a net cash outflow from financing activities of CNY -242,881,832.67 in Q3 2021, slightly higher than CNY -234,195,572.47 in Q3 2020[26] Assets and Liabilities - The total assets as of September 30, 2021, were ¥9,125,216,847.47, which is a 10.16% increase from the end of the previous year[5] - The total liabilities increased to ¥2,740,712,763.39 from ¥2,333,493,659.67, representing an increase of around 17%[20] - The equity attributable to shareholders at the end of Q3 2021 was ¥6,237,126,001.84, reflecting a 7.38% increase compared to the end of the previous year[5] - The equity attributable to shareholders of the parent company rose to ¥6,237,126,001.84, up from ¥5,808,408,894.46, reflecting an increase of about 7%[21] - Accounts receivable increased to ¥1,886,081,899.97 from ¥1,512,811,727.40, which is an increase of about 25%[17] - Inventory decreased slightly to ¥1,400,987,888.94 from ¥1,487,715,264.90, indicating a decline of approximately 6%[19] Growth and Strategic Initiatives - The company expects continued growth in operating performance, driven by increased sales and service revenue[9] - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2023[27] - New product launches contributed to a 10% increase in sales, with three new drugs approved in the last quarter[27] - Research and development investment increased by 18%, focusing on innovative drug formulations and delivery systems[27] - The company has set a revenue guidance of 5 billion RMB for the next fiscal year, representing a 20% growth target[27] - Strategic partnerships with local distributors are expected to enhance distribution efficiency and reduce costs by 15%[27] - The company is exploring potential acquisitions to diversify its product portfolio and enter new therapeutic areas[27] - Overall, the management expressed confidence in achieving long-term growth through strategic initiatives and market expansion[27] Research and Development - Research and development expenses increased to ¥94,465,763.49, compared to ¥75,364,143.77 in the previous year, marking a growth of about 25%[22] - Research and development investment increased by 18%, focusing on innovative drug formulations and delivery systems[27] Other Financial Metrics - The weighted average return on equity for Q3 2021 was 3.25%, an increase of 0.49 percentage points year-over-year[5] - The company reported non-recurring gains of ¥7,444,390.87 for Q3 2021, contributing to the overall profit growth[8] - The company reported a 3003% increase in current non-current liabilities, reaching approximately ¥31 million, primarily due to an increase in long-term borrowings maturing within one year[10] - The company recorded a 232% increase in asset disposal gains, totaling approximately ¥11.34 million, primarily from property disposals[12] - The company experienced a 128% increase in credit impairment losses, amounting to approximately -¥22.86 million, reflecting higher provisions for bad debts[12] - The company reported a 64% decrease in other income, totaling approximately ¥7.59 million, mainly due to a reduction in government subsidies[12] - The total number of common shareholders at the end of the reporting period was 30,401, with Tianjin Pharmaceutical Group Co., Ltd. holding 42.8% of the shares[14]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 3,640,421,324.94, representing a 10.64% increase compared to CNY 3,290,436,575.50 in the same period last year[16]. - The net profit attributable to shareholders of the listed company was CNY 462,548,368.85, a 43.00% increase from CNY 323,462,335.02 in the previous year[16]. - The net profit after deducting non-recurring gains and losses was CNY 444,974,234.80, up 38.11% from CNY 322,189,531.02 year-on-year[16]. - The net cash flow from operating activities was CNY 369,883,945.76, reflecting a 21.43% increase compared to CNY 304,615,906.50 in the same period last year[16]. - Basic earnings per share for the first half of 2021 were CNY 0.60, up 42.86% from CNY 0.42 in the same period last year[17]. - The diluted earnings per share were also CNY 0.60, reflecting a 42.86% increase compared to CNY 0.42 in the previous year[18]. - The weighted average return on equity increased to 7.66%, up 1.83 percentage points from 5.83% in the same period last year[18]. - The company's total operating costs amounted to ¥3,217,414,093.27, up from ¥2,992,547,262.42, reflecting a year-over-year increase of 7.52%[105]. - Net profit for the first half of 2021 was ¥472,600,792.23, representing a 41.73% increase from ¥333,826,199.42 in the previous year[107]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 8,999,122,093.70, an 8.64% increase from CNY 8,283,387,680.51 at the end of the previous year[16]. - The net assets attributable to shareholders of the listed company were CNY 6,043,844,318.57, which is a 4.05% increase from CNY 5,808,408,894.46 at the end of the previous year[16]. - Current liabilities rose to CNY 2,646,859,176.31, compared to CNY 2,163,851,493.10, reflecting an increase of approximately 22.39%[100]. - Total liabilities reached CNY 2,813,340,225.37, an increase from CNY 2,333,493,659.67, marking a growth of around 20.59%[101]. - The company's total assets increased to ¥8,465,664,582.65, compared to ¥7,757,700,810.99 at the end of the previous period, marking a growth of 9.12%[104]. - The company's total liabilities at the end of the first half of 2021 were RMB 1,342,524,878.17, showing the financial obligations of the company[124]. Revenue and Sales - The total revenue from sales of goods and services reached CNY 2,873,454,717.99, compared to CNY 2,237,857,833.80 in the first half of 2020, representing a growth of about 28.5%[117]. - Total sales revenue for the first half of 2021 reached approximately 188.84 million, with a significant increase of 8.48% compared to the previous period[78]. - The company reported a cash purchase of 357.81 million from its joint venture, indicating strong operational performance[77]. Research and Development - Research and development expenses rose by 42.40% to approximately ¥66.20 million, compared to ¥46.49 million in the previous year[37]. - The company has 331 patents, including 230 invention patents, supporting its research and development capabilities[32]. - The company has established a national-level enterprise technology center and five municipal-level technology centers to enhance innovation[32]. Market and Competition - The company is facing challenges and opportunities in the context of increasing competition and evolving consumer health demands[28]. - The company is actively exploring e-commerce models, utilizing B2B, B2C, and O2O strategies to expand marketing channels[26]. - The company has implemented a large product strategy, focusing on cardiovascular, respiratory, digestive, and anti-tumor medications[32]. Environmental Compliance - The company has established pollution prevention facilities, including activated carbon adsorption devices and wastewater treatment facilities, which are currently operating normally[61]. - The company is classified as a key pollutant discharge unit in Tianjin, with a focus on environmental management and compliance with relevant laws and regulations[61]. - There were no administrative penalties due to environmental issues during the reporting period[66]. Corporate Governance - Changes in management include the resignation of the Vice General Manager and the election of a new independent director[55]. - The company held its annual shareholder meeting on May 17, 2021, where 15 resolutions were approved, including the chairman's work report[54]. - The company has committed to ensuring compliance with state-owned asset management regulations to facilitate the approval process for the aforementioned transfer[72]. Financial Strategy - The company has strengthened data analysis and optimized fund management, conducting regular product value chain analysis to identify issues and adjust strategies accordingly[35]. - The company is committed to enhancing drug quality management in response to stricter regulatory requirements, which may lead to increased operational costs[52]. - The company’s financial strategy includes managing financial assets to optimize cash flow and minimize risks associated with credit and market fluctuations[144]. Related Party Transactions - The company has committed to avoiding related party transactions with its controlling shareholder to ensure fairness and transparency[72]. - The company reported a total of 84,110,605.98 RMB in transactions with its wholly-owned subsidiary for purchasing goods, accounting for 4.398% of similar transaction amounts[76]. - The company engaged in transactions totaling 28,193,332.68 RMB with its joint venture for purchasing goods, representing 1.474% of similar transaction amounts[76]. Accounting Policies - The company’s financial statements comply with the requirements of the enterprise accounting standards, reflecting the financial status as of June 30, 2021[134]. - There were no significant changes in accounting policies or estimates during the reporting period[198]. - The company applies significant judgment and estimates in accounting policies due to inherent uncertainties in operating activities[199].

Financial Performance - In 2020, the company achieved a net profit of CNY 670,720,947.03, an increase of 5.78% compared to CNY 625,568,681.66 in 2019[3]. - The total operating revenue for 2020 was CNY 6,603,652,015.11, representing a decrease of 5.58% from CNY 6,993,881,697.60 in 2019[15]. - The net profit attributable to shareholders for the fourth quarter was CNY 184,903,202.00, showing an increase compared to the previous quarter's CNY 153,338,813.11[21]. - The company reported a net profit of CNY 661,704,350.13 for the current period, up from CNY 625,568,681.66 in the previous period, reflecting a growth of about 5.4%[19]. - The net profit attributable to the parent company was CNY 661.70 million, reflecting a decline in profitability[38]. - The company reported a significant increase in net cash flow from operating activities, which rose by 35.51% to CNY 671.42 million[39]. - The company reported a net profit excluding non-recurring gains and losses of CNY 633,187,164.91, up 6.12% from CNY 596,675,465.54 in 2019[17]. Assets and Liabilities - The company's total assets at the end of 2020 were CNY 8,283,387,680.51, up 5.61% from CNY 7,843,177,241.57 at the end of 2019[17]. - As of December 31, 2020, the company's total assets amounted to CNY 8,283.39 million, with net assets attributable to the parent company at CNY 5,808.41 million[38]. - The company reported a total accounts receivable balance of RMB 1,651.76 million as of December 31, 2020[197]. - The company's inventory balance was RMB 1,528.16 million as of December 31, 2020, which includes raw materials, products, and medical devices[199]. Research and Development - The company holds 324 patents, with 228 being invention patents, indicating a strong focus on innovation and R&D[25]. - The total R&D expenditure amounted to 126,492,800 CNY, representing 1.92% of total revenue, with 705 R&D personnel, accounting for 14.57% of the total workforce[48]. - The company invested 126.49 million yuan in technology development, resulting in 30 new patent authorizations and 11 new trademark registrations[35]. - The company invested a total of 12,649.28 million RMB in R&D, initiating 19 new product development projects in 2020[71]. - The company is actively involved in research and development of new technologies to enhance product efficacy and safety[60]. Market and Product Development - The company has a diverse product portfolio with 99 exclusive production varieties and 216 varieties included in the national medical insurance list[31]. - The company achieved a sales revenue of 94.65 million yuan for the Niuhuang Qingxin Wan product, representing a year-on-year growth of 241%[33]. - The company is expanding its product line to include treatments for diabetes and male health, with new products like Jinqi Jiangtang Pian and Haima Bujin Wan[63]. - The company plans to expand its "Internet+" marketing strategy to enhance e-commerce operations and improve sales channels[26]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[161]. Corporate Governance - The company has established a comprehensive internal control management system in accordance with regulatory requirements[188]. - The company maintained strict information disclosure practices, adhering to both Chinese and Singaporean regulations[188]. - The company’s governance structure includes an audit committee, strategic committee, nomination committee, and remuneration and assessment committee[186]. - The independent directors actively participated in committees, ensuring oversight and governance compliance[186]. - The company has not faced any significant discrepancies with the regulations set by the China Securities Regulatory Commission[183]. Risk Management - The company faces risks from the normalization of centralized drug procurement, which has significantly impacted drug prices and market dynamics[101]. - The company anticipates a decline in profitability due to increased competition and changes in sales models affecting both the medical and OTC markets[101]. - The company acknowledges the ongoing risks associated with drug quality due to environmental factors and human error, which could impact public health and operational stability[103]. - New drug development poses significant risks, including high investment, long cycles, and potential failures, exacerbated by stricter regulatory standards introduced in 2020[103]. Employee and Social Responsibility - The company provided assistance to over 1,000 employees in need, utilizing approximately 5.1 million RMB in support funds[137]. - The company has implemented mutual insurance plans for employees, costing approximately 750,000 RMB over three years[137]. - The total number of employees in the parent company was 3,917, with a combined total of 4,840 employees across the parent and major subsidiaries[176]. - The employee composition includes 1,623 production personnel, 1,802 sales personnel, 705 technical personnel, 220 financial personnel, and 490 administrative personnel[177]. Shareholder Returns - The company plans to distribute a cash dividend of 3.0 RMB per 10 shares (including tax) for the fiscal year 2020, pending approval at the annual shareholders' meeting[106]. - The company reported a net profit of 661,704,350.13 RMB for 2020, with a profit distribution ratio of 35.08%[107]. - The company has implemented a three-year shareholder return plan for 2020-2022, which was approved at the 2019 annual shareholders' meeting[105]. Industry Trends - The pharmaceutical industry achieved a total revenue of ¥2,485.73 billion in 2020, representing a year-on-year growth of 4.5%[54]. - The COVID-19 pandemic has accelerated demand growth and R&D in the pharmaceutical sector, leading to a temporary performance boost for related companies[57]. - The implementation of the new Pharmacopoeia on December 30, 2020, is expected to bring significant changes to the pharmaceutical industry, particularly in traditional Chinese medicine[57]. - The company anticipates that the pharmaceutical industry will continue to grow, driven by an aging population and ongoing healthcare reforms in China[56].